Prosecution Insights
Last updated: November 20, 2026

Sahar Inam, USPTO Patent Examiner

Listed by the USPTO as INAM, SAHAR

Tech Center 1600 • Art Units: 1600 1622

This examiner grants 100% of resolved cases

Analysis

INAM, SAHAR handles matters in Technology Center 1600 and art unit 1600. The profile contains 2 resolved cases, and the allowance rate is 100.0%. The median days to allowance are 986. The small resolved-case base makes the outcome metric a limited record, while the timing figure supplies additional context for prosecution planning.

The interview lift is 0.0%, so the available data does not associate interviews with an uplift in this record. The listed companies are Revolution Medicines Inc., Antecip Bioventures Ii LLC, and University of Florida Research Foundation Inc. The listed firms are Clark+Elbing LLP, Clark+Elbing LLP - Revolution Medicines, Inc., and K&L Gates LLP-Boston.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

100.0%
Allow Rate
+40.0% vs TC avg
27
Total Applications
+0.0%
Interview Lift
986
Avg Prosecution Days
Based on 2 resolved cases, 2023–2026

Rejection Statute Breakdown

1.5%
§101 Eligibility
21.5%
§102 Novelty
40.0%
§103 Obviousness
32.3%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18874975 THIAZOLIDINEDIONES FOR THE TREATMENT OF MUSCULAR DYSTROPHIES Non-Final OA University of Florida Research Foundation, Incorporated
18572110 Aminopyridine-based MTA-Cooperative PRMT5 Inhibitors Non-Final OA Mirati Therapeutics, Inc.
17780786 TREATMENT OF HEPATITIS B VIRUS (HBV) INFECTION Final Rejection UCL BUSINESS LTD
18845317 SUBSTITUTED IMIDAZO[1,5-A]PYRIDINE N-HETEROCYCLIC CARBENE (NHC) LIGANDS, CATALYST COMPLEXES THEREOF, AND METHODS USING SAME Non-Final OA Rutgers, The State University of New Jersey
18805212 PROLYL HYDROXYLASE DOMAIN INHIBITOR FOR TREATING HEMORRHAGIC OR BURN SHOCK Non-Final OA THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Sahar Inam's allowance rate?

100.0% of resolved applications examined by Sahar Inam were allowed (2 resolved cases), compared with 36.5% across Art Unit 1600 over the last five years.

Does an interview help with examiner Sahar Inam?

This examiner's interview lift is +0.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Sahar Inam take to allow a patent?

Applications allowed by Sahar Inam took 986 days on average from filing to allowance.

Which art unit does examiner Sahar Inam work in?

Sahar Inam examines applications in Art Unit 1600 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month